Aitor Aparicio-García
Research Interests
Aitor Aparicio-García has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Alba Ancochea-Díaz
Spanish Federation of Rare Diseases (FEDER), 28009 Madrid, Spain
1 shared publication - Greta Arias-Merino
Institute of Rare Diseases Research (IIER), Instituto de Salud Carlos III, Madrid, Spain
1 shared publication - Juan Benito-Lozano
Affiliations Institute of Rare Diseases Research (IIER), Instituto de Salud Carlos III (ISCIII), Madrid, Spain, Universidad Nacional de Educación a Distancia (UNED), Madrid, Spain
1 shared publication - Manuel Posada de la Paz
Instituto de Investigación de Enfermedades Raras (IIER), Instituto de Salud Carlos III (ISCIII) Madrid Spain
1 shared publication - Mario Gómez-Martínez
Institute of Rare Diseases Research (IIER), Instituto de Salud Carlos III, 28029 Madrid, Spain
1 shared publication - Verónica Alonso-Ferreira
Institute of Rare Diseases Research, Instituto de Salud Carlos III, Madrid, Spain.
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 26 May 2022
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 19 (11) , 6456
Diagnostic Process in Rare Diseases: Determinants Associated with Diagnostic Delay
Many people living with rare disease (RD) report a difficult diagnostic process from the symptom onset until they obtain the definitive diagnosis. The aim of this study was thus to ascertain the diagnostic process in RDs, and explore the determinants related with having to wait for more than one year in this process (defined as “diagnostic delay”). We conducted a case–control study, using a purpose-designed form from the Spanish Rare Diseases Patient Registry for data-collection purposes. A descriptive analysis was performed and multivariate backward logistic regression models fitted. Based on data on 1216 patients living with RDs, we identified a series of determinants associated with experiencing diagnostic delay. These included: having to travel to see a specialist other than that usually consulted in the patient’s home province (OR 2.1; 95%CI 1.6–2.9); visiting more than 10 specialists (OR 2.6; 95%CI 1.7–4.0); being diagnosed in a region other than that of the patient’s residence at the date of symptom onset (OR 2.3; 95%CI 1.5–3.6); suffering from a RD of the nervous system (OR 1.4; 95%CI 1.0–1.8). In terms of time taken to see a specialist, waiting more than 6 months to be referred from the first medical visit was the period of time which most contributed to diagnostic delay (PAR 30.2%). In conclusion, this is the first paper to use a collaborative study based on a nationwide registry to address the diagnostic process of patients living with RDs. While the evidence shows that the diagnostic process experienced by these persons is complex, more studies are needed to determine the implications that this has for their lives and those of their families at a social, educational, occupational, psychological, and financial level.
- 26 May 2022
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 19 (11) , 6456
Top Cited PapersOpen AccessDiagnostic Process in Rare Diseases: Determinants Associated with Diagnostic Delay
Many people living with rare disease (RD) report a difficult diagnostic process from the symptom onset until they obtain the definitive diagnosis. The aim of this study was thus to ascertain the diagnostic process in RDs, and explore the determinants related with having to wait for more than one year in this process (defined as “diagnostic delay”). We conducted a case–control study, using a purpose-designed form from the Spanish Rare Diseases Patient Registry for data-collection purposes. A descriptive analysis was performed and multivariate backward logistic regression models fitted. Based on data on 1216 patients living with RDs, we identified a series of determinants associated with experiencing diagnostic delay. These included: having to travel to see a specialist other than that usually consulted in the patient’s home province (OR 2.1; 95%CI 1.6–2.9); visiting more than 10 specialists (OR 2.6; 95%CI 1.7–4.0); being diagnosed in a region other than that of the patient’s residence at the date of symptom onset (OR 2.3; 95%CI 1.5–3.6); suffering from a RD of the nervous system (OR 1.4; 95%CI 1.0–1.8). In terms of time taken to see a specialist, waiting more than 6 months to be referred from the first medical visit was the period of time which most contributed to diagnostic delay (PAR 30.2%). In conclusion, this is the first paper to use a collaborative study based on a nationwide registry to address the diagnostic process of patients living with RDs. While the evidence shows that the diagnostic process experienced by these persons is complex, more studies are needed to determine the implications that this has for their lives and those of their families at a social, educational, occupational, psychological, and financial level.